Orforglipron offers greater weight loss for people with diabetes than oral semaglutide
Abstract
Novel weight-loss pill orforglipron (Emgality; Eli Lilly) offers patients with type 2 diabetes mellitus (T2DM) better blood sugar control and more weight loss than semaglutide — the only other GLP-1 receptor agonist pill currently available — according to the results of a phase III clinical trial. Publishing the findings of the ‘ACHIEVE-3‘ study in The […]
Fields of Study & Subjects
Diabetes Treatment and Management
Pharmacology and Obesity Treatment
Diabetes Management and Research
Publication details
- Journal / source
- Pharmaceutical journal/The pharmaceutical journal
- Publication date
- 1 January 2026
- Language
- EN